Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).
Saved in:
| Title: | Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). |
|---|---|
| Authors: | Opdam M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ultee N; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Geenen JJJ; Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rossum AGJ; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Data Center, Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Biometrics Division, Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wesseling J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Menezes RX; Biostatistics Centre, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Oosterkamp HM; Department of Medical Oncology, Haaglanden Medisch Centrum, The Hague, the Netherlands., Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands. Electronic address: s.linn@nki.nl. |
| Corporate Authors: | MATADOR trialists' group for the Dutch Breast Cancer Research Group (BOOG) |
| Source: | Breast (Edinburgh, Scotland) [Breast] 2026 Jun; Vol. 87, pp. 104749. Date of Electronic Publication: 2026 Mar 13. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41864056 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Opdam+M%22">Opdam M</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Ultee+N%22">Ultee N</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Geenen+JJJ%22">Geenen JJJ</searchLink>; Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Rossum+AGJ%22">van Rossum AGJ</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Mandjes+IAM%22">Mandjes IAM</searchLink>; Data Center, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Balduzzi+S%22">Balduzzi S</searchLink>; Biometrics Division, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Hofland+I%22">Hofland I</searchLink>; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Wesseling+J%22">Wesseling J</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Menezes+RX%22">Menezes RX</searchLink>; Biostatistics Centre, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Oosterkamp+HM%22">Oosterkamp HM</searchLink>; Department of Medical Oncology, Haaglanden Medisch Centrum, The Hague, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Linn+SC%22">Linn SC</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands. Electronic address: s.linn@nki.nl. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22MATADOR+trialists'+group+for+the+Dutch+Breast+Cancer+Research+Group+%28BOOG%29%22">MATADOR trialists' group for the Dutch Breast Cancer Research Group (BOOG)</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229213011%22">Breast (Edinburgh, Scotland)</searchLink> [Breast] 2026 Jun; Vol. 87, pp. 104749. <i>Date of Electronic Publication: </i>2026 Mar 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>9213011 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-3080 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209609776%22">09609776 </searchLink><i>NLM ISO Abbreviation: </i>Breast <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41864056 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.breast.2026.104749 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 104749 Titles: – TitleFull: Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Opdam M – PersonEntity: Name: NameFull: Ultee N – PersonEntity: Name: NameFull: Geenen JJJ – PersonEntity: Name: NameFull: van Rossum AGJ – PersonEntity: Name: NameFull: Mandjes IAM – PersonEntity: Name: NameFull: Balduzzi S – PersonEntity: Name: NameFull: Hofland I – PersonEntity: Name: NameFull: Wesseling J – PersonEntity: Name: NameFull: Menezes RX – PersonEntity: Name: NameFull: Oosterkamp HM – PersonEntity: Name: NameFull: Linn SC IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1532-3080 Numbering: – Type: volume Value: 87 Titles: – TitleFull: Breast (Edinburgh, Scotland) Type: main |
| ResultId | 1 |